Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRT-Y90 Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma
NCT02167711Phase 2Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2014
- Primary completion
- Jan 2023
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of yttrium-90 radioembolization in cholangiocarcinoma (CCA), sponsored by The Chinese University of Hong Kong. Primary endpoint: Overall survival at 2 years. Started Sep 2014; status: completed.
02
Drugs
yttrium-90 radioembolization
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT02167711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167711.